{"title":"Emergency Care for Patients with Cancer on Immune Checkpoint Inhibitors: A Retrospective Analysis of Immune-Related Adverse Events","authors":"Alice Ferrua , Jacopo Davide Giamello , Chiara Fulcheri , Michela Milanesio , Giulia Bernardi , Elena Fea , Salvatore D’Agnano , Nicoletta Artana , Daniela Caruso , Giovanna Greco , Tiziana Ponza , Enrico Lupia , Luigi Fenoglio , Giuseppe Lauria , Gianmauro Numico","doi":"10.1016/j.jemermed.2025.08.025","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but can lead to immune-related adverse events (irAEs), some of which require emergency care.</div></div><div><h3>Objective</h3><div>To evaluate the prevalence, clinical features and outcomes of emergency department (ED) visits related to irAEs among patients receiving ICIs.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed ED visits from 2013 to 2021 among patients with solid tumors treated with ICIs at a single tertiary cancer center in Italy. Each visit was independently reviewed and classified as definitely, potentially, or not related to irAEs.</div></div><div><h3>Results</h3><div>Of 457 ED visits from 216 patients, 27 (5.9%) were definitely and 15 (3.3%) potentially related to irAEs. The most frequent irAEs were pneumonitis (<em>n</em> = 19), colitis (<em>n</em> = 5), and hepatitis (<em>n</em> = 3). Dyspnea was more common in irAE-related visits (28.6% vs 13%, <em>p</em> = 0.006). 74.1% of irAE-related visits resulted in hospital admission and 30-day mortality was 14.3%. The median time from ICI initiation to ED presentation for irAEs was 21 weeks.</div></div><div><h3>Conclusions</h3><div>irAEs account for a significant portion of ED visits in patients receiving ICIs, with pneumonitis being the most frequent. Emergency clinicians should be aware of this delayed toxicity spectrum, especially in patients presenting with respiratory symptoms.</div></div>","PeriodicalId":16085,"journal":{"name":"Journal of Emergency Medicine","volume":"78 ","pages":"Pages 235-240"},"PeriodicalIF":1.3000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Emergency Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0736467925003336","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"EMERGENCY MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but can lead to immune-related adverse events (irAEs), some of which require emergency care.
Objective
To evaluate the prevalence, clinical features and outcomes of emergency department (ED) visits related to irAEs among patients receiving ICIs.
Methods
We retrospectively reviewed ED visits from 2013 to 2021 among patients with solid tumors treated with ICIs at a single tertiary cancer center in Italy. Each visit was independently reviewed and classified as definitely, potentially, or not related to irAEs.
Results
Of 457 ED visits from 216 patients, 27 (5.9%) were definitely and 15 (3.3%) potentially related to irAEs. The most frequent irAEs were pneumonitis (n = 19), colitis (n = 5), and hepatitis (n = 3). Dyspnea was more common in irAE-related visits (28.6% vs 13%, p = 0.006). 74.1% of irAE-related visits resulted in hospital admission and 30-day mortality was 14.3%. The median time from ICI initiation to ED presentation for irAEs was 21 weeks.
Conclusions
irAEs account for a significant portion of ED visits in patients receiving ICIs, with pneumonitis being the most frequent. Emergency clinicians should be aware of this delayed toxicity spectrum, especially in patients presenting with respiratory symptoms.
期刊介绍:
The Journal of Emergency Medicine is an international, peer-reviewed publication featuring original contributions of interest to both the academic and practicing emergency physician. JEM, published monthly, contains research papers and clinical studies as well as articles focusing on the training of emergency physicians and on the practice of emergency medicine. The Journal features the following sections:
• Original Contributions
• Clinical Communications: Pediatric, Adult, OB/GYN
• Selected Topics: Toxicology, Prehospital Care, The Difficult Airway, Aeromedical Emergencies, Disaster Medicine, Cardiology Commentary, Emergency Radiology, Critical Care, Sports Medicine, Wound Care
• Techniques and Procedures
• Technical Tips
• Clinical Laboratory in Emergency Medicine
• Pharmacology in Emergency Medicine
• Case Presentations of the Harvard Emergency Medicine Residency
• Visual Diagnosis in Emergency Medicine
• Medical Classics
• Emergency Forum
• Editorial(s)
• Letters to the Editor
• Education
• Administration of Emergency Medicine
• International Emergency Medicine
• Computers in Emergency Medicine
• Violence: Recognition, Management, and Prevention
• Ethics
• Humanities and Medicine
• American Academy of Emergency Medicine
• AAEM Medical Student Forum
• Book and Other Media Reviews
• Calendar of Events
• Abstracts
• Trauma Reports
• Ultrasound in Emergency Medicine